Quanterix to Participate in Upcoming Investor Conferences

Quanterix (Nasdaq: QTRX) said its executive leadership will participate in two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/26/2026 - 08:33 AM EST

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March:

46th Annual TD Cowen Healthcare Conference
Format: Fireside chat and one-on-one meetings
Date: Wednesday, March 4, 2026
Time: 11:50 am ET
Webcast: Click here

Leerink Global Healthcare Conference 2026
Format: Fireside chat and one-on-one meetings
Date: Monday, March 9, 2026
Time: 1:00 pm ET
Webcast: Click here

Interested parties may access a live and recorded webcast of the fireside chats on the Investors section of the company’s website at www.quanterix.com.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.